Monash IVF chief executive and managing director James Thiedeman has resigned after eight years at the helm to take up a role at an unlisted healthcare organisation.
The company says Mr Thiedeman, who has led the ASX-listed firm for eight years, has agreed to serve out his six-month notice period to ensure a smooth transition to his replacement.
Mr Thiedeman has consistently led the company to increased profits and earnings through acquisitions and market share expansion after it first listed on the ASX in June 2014.
In the 2016 financial year, Monash's net profit leapt 34.6 per cent to $28.78 million, while revenue also jumped 25.3 per cent to $156.56 million.
Monash chairman Richard Davis thanked Mr Tiedeman for substantially growing the company's domestic footprint, expanding overseas and broadening the scope of its services into women's imaging.
"James has built a strong team around him who are well positioned to continue to drive the company's growth agenda and continue to deliver world class care to our patients," Mr Davis said in a statement.
Monash said it would consider both internal and external candidates to take over from Mr Tiedeman.
Share
